StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals SBC expense — Research and development by Quarter

SBC expense — Research and development ($M) ($M)

QuarterlyAnnual

Vertex Pharmaceuticals SBC expense — Research and development: $104M in Q2 2026, up 4.8% from a year earlier.

Latest, Q2 2026
104
Period ended Jun 30, 2026
Change on a year earlier
+4.8%
99.6 in Q2 2025
History
36 quarters
Since Q1 2017
Sources
31
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Note (Stock-based Compensation).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSBC expense — Research and development ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026104+4.8%Form 10-Q (filed 2026-08-04) ↗
Q1 2026Mar 31, 2026102+1.6%Form 10-Q (filed 2026-05-05) ↗
Q4 2025Dec 31, 202599.7+1.4%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025116+4.5%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 202599.6+2.6%Form 10-Q (filed 2026-08-04) ↗
Q1 2025Mar 31, 2025100-16.2%Form 10-Q (filed 2026-05-05) ↗
Q4 2024Dec 31, 202498.3-20.1%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024111+36.9%Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 202497.1+30.3%Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 2024119+56.5%Form 10-Q (filed 2025-05-06) ↗
Q4 2023Dec 31, 2023123+80.9%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 202381.1+1.4%Form 10-Q (filed 2024-11-05) ↗
Q2 2023Jun 30, 202374.5+7.2%Form 10-Q (filed 2024-08-02) ↗
Q1 2023Mar 31, 202376.3-5.1%Form 10-Q (filed 2024-05-07) ↗
Q4 2022Dec 31, 202268-5.4%Form 10-K (filed 2025-02-13) ↗
Q3 2022Sep 30, 202280+31.1%Form 10-Q (filed 2023-11-07) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals SBC expense — Research and development ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/sbc-exp-rd

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.